Company intelligence / Profile preview

AVIPERO Ltd.

Edinburgh, Scotland, United Kingdomavipero.com ↗

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

AVIPERO is developing allosteric modulators of integrins for treating Triple Negative Breast Cancer and other conditions. Their approach aims to refine integrins and tissues to restore cells to their original state, modifying disease progression while reducing severe side effects associated with traditional treatments. Currently, their pipeline includes AVI-001 and AVI-002, both in preclinical stage.

Therapeutic areas: OtherOncologyNeurology
Modalities: Small molecule drugAllosteric modulators
Industry: Biotech

Drug pipeline

2 assets

AVI001

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on AVIPERO Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVIPERO Ltd..

Explore the full profile